Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9LH10)

Drug Name
Vadastuximab talirine Drug Info
Synonyms
vadastuximab talirine; Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [1]
Myelodysplastic syndrome 2A37 Phase 2 [1]
Cross-matching ID
PubChem CID
122706909
CAS Number
CAS 1436390-64-5
TTD Drug ID
DM9LH10

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Myeloid cell surface antigen CD33 (CD33)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gemtuzumab ozogamicin DMJ2O7B Acute myeloid leukaemia 2A60 Approved [2]
Actimab-A DMKBIPR Acute myeloid leukaemia 2A60 Phase 2 [1]
BI-836858 DMUVMY9 Myelodysplastic syndrome 2A37 Phase 2 [3]
Actimab-MDS DMP8EEX Myelodysplastic syndrome 2A37 Phase 2 [4]
GTB-3550 DMK2RIB Acute myelogenous leukaemia 2A41 Phase 1/2 [5]
SGN-CD33A DMRC7PI Acute myeloid leukaemia 2A60 Phase 1/2 [6]
CART33 cells DM81JIT Myeloid leukaemia 2B33.1 Phase 1/2 [7]
CD33-specific gene-engineered T cells DMM35D2 Acute myeloid leukaemia 2A60 Phase 1/2 [8]
Anti-CD33 CAR-T cells DM9NPF6 Myeloid leukaemia 2B33.1 Phase 1/2 [9]
HuM-195-Ac-225 DMIU1HY Acute myelogenous leukaemia 2A41 Phase 1/2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Myeloid cell surface antigen CD33 (CD33) TTJVYO3 CD33_HUMAN Antagonist [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4:197-205.
3 The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 Jul;28(4):143-53.
4 Clinical pipeline report, company report or official report of Actinium Pharmaceuticals
5 Clinical pipeline report, company report or official report of GT Biopharma.
6 SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63.
7 ClinicalTrials.gov (NCT01864902) Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
8 ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
9 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
10 J Clin Oncol 29: 2011 (suppl; abstr 6516).